| 查看: 1802 | 回复: 101 | |||
| 当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖 | |||
[交流]
【转自药渡网】Teva 报告了乐观哮喘临床3期评估结果
|
|||
|
Teva 对临床3期评估了对于哮喘患者干粉吸入器 (MDPIs)吸入Fluticasone Propionate /Salmeterol和多剂量Fluticasone Propionate 的实验效果，实验数据很好。研究表明通过使用干粉吸入器 (MDPI)，低剂量与安慰剂相比具有更大的效能，结果展示 Teva 扩大呼吸的研发能力和支持其核心，呼吸驱动MDPI平台的发展。最初的结果显示fluticasone propionate/salmeterol MDPI的不良事件可以和fluticasone propionate治疗和安慰剂媲美。 相关阅读： Teva Reports Positive Top-Line Results from Phase III Trials Evaluating Fluticasone Propionate/Salmeterol and Fluticasone Propionate Multidose Dry Powder Inhalers (MDPIs) in Patients with Asthma Studies demonstrate greater efficacy with lower doses delivered via multidose dry-powder inhaler (MDPI) compared to placebo Results showcase Teva’s expanding respiratory R&D capabilities and support advancement of core, breath-actuated MDPI platform Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced positive top-line results from three Phase III clinical studies designed to evaluate the efficacy and safety of fluticasone propionate/salmeterol, a combination inhaled corticosteroid (ICS) and long-acting beta agonist (LABA) delivered via a multidose dry powder inhaler (MDPI) and fluticasone propionate, an ICS monotherapy delivered via a MDPI in adolescent and adult patients with asthma. Top-line data showed that the studies met their primary endpoints. Importantly, the studies also showed similar overall safety profiles as compared to therapies in the corresponding drug classes. “These data support Teva’s commitment to further optimize the treatment of respiratory disease through the development of devices and therapies that help address the needs of patients and physicians,” said Tushar Shah, MD, Senior Vice President, Teva Global Respiratory Research and Development. “With this dual development program we have demonstrated clinically significant levels of effectiveness, by delivering combination and monotherapy at lower doses utilizing our core, breath-actuated, MDPI platform.” Fluticasone propionate/salmeterol MDPI demonstrated, in the double-blind studies, clinically relevant and greater benefit at all doses (50/12.5, 100/12.5, and 200/12.5 mcg BID nominal delivered doses) versus placebo and versus respective monotherapy (fluticasone propionate) in the improvement of lung function as measured by the change from baseline in trough Forced Expiratory Volume in one second (FEV1) at the 12-week trial period and standardized baseline-adjusted area under the effect curve FEV1 from time 0 to 12 hours post dose at Week 12. This initial set of results shows the adverse event profile of fluticasone propionate/salmeterol MDPI was comparable to fluticasone propionate monotherapy and placebo. Fluticasone propionate MDPI also demonstrated clinically relevant and greater benefit at all doses (50, 100, and 200 mcg BID nominal delivered doses) versus placebo in the improvement of lung function, in the double-blind studies. The initial set of results shows the adverse event profile of fluticasone propionate MDPI was comparable to placebo. The majority of adverse events were mild to moderate in severity. There were no drug-related deaths across any of the trials. Further analyses of additional efficacy and safety data are ongoing. Full results will be submitted for presentation at future scientific meetings and for publication in peer reviewed journals. “We have made significant progress in furthering our respiratory pipeline with a focus on a complete asthma management system utilizing our breath-actuated MDPI platform,” said Michael Hayden, M.D., Ph.D., President of Global R&D and Chief Scientific Officer at Teva. “We have successfully developed and launched products that utilize our breath-actuated MDPI platform in select markets around the world. These data support the broadening of our portfolio in using this technology to develop and deliver additional respiratory therapeutic options.” Regulatory submissions for both fluticasone propionate/salmeterol MDPI and fluticasone propionate MDPI in the U.S. are planned for 2016. |
回复此楼» 猜你喜欢
272分材料子求调剂
已经有36人回复
-
275求调剂
已经有8人回复
-
调剂求收留
已经有5人回复
-
一志愿211，化学学硕，310分，本科重点双非，求调剂
已经有20人回复
-
070300化学学硕311分求调剂
已经有19人回复
-
材料与化工调剂
已经有13人回复
-
材料与化工调剂
已经有33人回复
-
复试调剂
已经有7人回复
-
一志愿哈工大 085600 277 12材科基求调剂
已经有17人回复
-
还有化工二轮调剂的学校吗
已经有47人回复
» 抢金币啦！回帖就可以得到:
-
沈阳化工大学环境学院生物技术与工程（无数学）、环境科学与工程等可调剂
+1/482
-
长江大学化工学院2026年硕士研究生调剂公告（理、工均收）
+1/90
-
中国水产科学研究院黄海水产研究所张旭志课题组招聘 可穿戴传感器研究 科研助理
+1/83
-
延安大学接收化学与化工学院接收调剂生（化学、化工学硕和材料与化工专硕）
+2/48
-
济南大学 环境科学 环境工程 硕士招生 调剂 信息
+1/41
-
黑龙江科技大学化工 环境工程调剂
+3/33
-
招收化学、海洋科学、材料、环境专业调剂
+3/22
-
22408 302分求调剂
+1/15
-
C13、N15稳定同位素标记植物，助力科研人高效开展试验
+1/12
-
大连大学-贵州省煤炭洁净利用重点实验室联合培养研究生 化学5人+环境工程7人
+1/12
-
大连大学 化学专业 招收26年硕士研究生调剂
+1/11
-
★上海★上海工程技术大学·环境与资源创新中心（ICER）接收化工材料环境等学科调剂生
+1/8
-
天津商业大学生物技术与食品科学学院083200；086000专业调剂招生
+1/7
-
天津商业大学生物技术与食品科学学院调剂招生
+1/7
-
中国科学技术大学-安徽大学高薪联合招聘博士后/副研究员
+1/7
-
最后调剂名额，丽水学院材料与能源工程学院
+1/6
-
河南理工大学化学化工学院招收材料、化工类专业调剂研究生
+1/3
-
线上复试：河南理工大学 化工学院 接收调剂硕士研究生
+1/2
-
江西科技师范大学申亮组招研究生（高分子化学专业）
+1/2
-
上海应用技术大学招生调剂研究生
+1/1
83楼2015-11-20 16:21:10
简单回复
2015-11-20 15:50
回复
药渡(金币+1): 谢谢参与
。 发自小木虫Android客户端
江南的竹10楼
2015-11-20 15:58
回复
药渡(金币+1): 谢谢参与
。 [ 发自小木虫客户端 ]
